Sun Pharma Says Ilumya US Growth Can Recover in Few Quarters
Key highlights
- Sun Pharma expects US Ilumya growth to return to typical patterns over the next few quarters.
- Global Innovative Medicines sales rose 6.9% year on year to USD356 million in Q2 FY27.
- Sun Pharma planned an Ilumya psoriatic arthritis soft launch in November, followed by a full launch in subsequent months.
- India formulations sales grew 17.3% year on year to Rs 5,552.3 crore in Q2 FY27.
powered by IRIS

Sun Pharma said US Ilumya growth slowed in Q2 FY27 because of market and execution factors, but management expects interventions and the new psoriatic arthritis indication to restore more typical growth over the next few quarters. Global Innovative Medicines sales nevertheless rose 6.9% year on year to USD356 million.
Know Sun Pharmaceutical Industries inside out
Results, valuation, peers and who's buying, in one view.
Why did Sun Pharma's US Ilumya growth slow?
Sun Pharma said the US Ilumya slowdown reflected a mix of market conditions and execution issues in Q2 FY27. Richard Ascroft said on the October 30, 2026 earnings call that management had identified several causes and had already introduced interventions, but he did not disclose Ilumya sales, the precise operational issues or their individual financial effects.
The company identified Ilumya as a key reason for slower growth in Global Innovative Medicines, although that business still increased 6.9% year on year to USD356 million in Q2 FY27. Innovative Medicines represented 21.1% of Sun Pharma's quarterly sales, with ex-US Ilumya, Cequa and Odomzo among the products supporting growth.
Sun Pharma's wider US business recorded USD455 million of sales, down 8.2% year on year, largely because of lenalidomide erosion. That business grew 6.5% quarter on quarter after five generic launches, separating the broader US sales decline from the brand-specific Ilumya slowdown.
When does Sun Pharma expect Ilumya growth to recover?
Sun Pharma expects Ilumya to return to more typical growth patterns over the next few quarters. Ascroft linked this expectation to the interventions already implemented and to the US launch of Ilumya for active psoriatic arthritis, while providing neither a brand-specific sales target nor a precise quarter for recovery.
Sun Pharma said the commercial work for psoriatic arthritis is already included in its existing sales-force model. Some prescriptions are expected from dermatologists, while the company will extend coverage to rheumatologists; its field force was being trained on the updated prescribing information during the October 30, 2026 call.
The company had planned a soft launch in November, followed by a full launch in the subsequent months, after US approval for adults with active psoriatic arthritis. Management said launch costs were within the overall budget rather than a separate one-off expense, so it did not identify an additional launch-cost figure.
How could psoriatic arthritis support Sun Pharma's Ilumya sales?
Sun Pharma said the psoriatic arthritis approval extends Ilumya into a related treatment setting, with about one-third of plaque psoriasis patients also having comorbid psoriatic arthritis. Management did not provide revenue guidance for the new indication or quantify how much it could add to the Ilumya franchise.
Management described Ilumya as the only healthcare-provider-administered interleukin-23, or IL-23, therapy for psoriatic arthritis, which rheumatologists can administer quarterly. Ascroft said competing healthcare-provider-administered products require more frequent use, and argued that Ilumya's administration model can help patients who require additional care.
Sun Pharma also said rheumatologists are familiar with physician-administered “buy-and-bill” medicines, which management believes can support early use of Ilumya. This is management's commercial expectation rather than a reported prescription outcome; the stated test over the next few quarters is whether rheumatology outreach and the new indication improve growth.
Got a follow-up? Ask IRIS
Is Sun Pharma's Ilumya slowdown limited to the United States?
Sun Pharma said Ilumya continued to perform well outside the US, making the disclosed slowdown specific to its US business. In Japan, management said the Japanese Society for Psoriasis Research ranked Ilumya number two among biologics for new patients across 73 main hospitals, an improvement from the previous year.
Emerging Markets formulations revenue rose 7.6% year on year to USD350 million in Q2 FY27, while constant-currency growth was 7.4%. These markets accounted for 20.7% of consolidated revenue, and management cited both branded generics and Innovative Medicines, including Ilumya in Romania and Brazil, as growth drivers.
This comparison leaves different priorities by geography. Sun Pharma is addressing US execution and launching into psoriatic arthritis, while it reported continued international momentum for Ilumya; it also expanded its innovative portfolio through an agreement with LIB Therapeutics for lerodalcibep outside the US and China.
What do Sun Pharma's wider Q2 FY27 results show?
Sun Pharma's India formulations sales increased 17.3% year on year to Rs 5,552.3 crore in Q2 FY27 and accounted for 34.5% of consolidated sales. Its share of the Indian pharmaceutical market was 8.6% in the 12 months to September 2026, compared with 8.3% in the corresponding earlier period.
For the first half of FY27, Sun Pharma reported sales of Rs 31,283.6 crore, up 11% year on year, while earnings before interest, tax, depreciation and amortisation, or EBITDA, rose 3.8% to Rs 9,161.6 crore. Q2 EBITDA was Rs 4,743.9 crore, up 4.8%, and the margin was 29.3%; management noted that Q2 FY26 had benefited from lenalidomide sales.
Research and development spending was Rs 778.4 crore in Q2 FY27, equal to 4.8% of sales, with Innovative R&D accounting for 32.4% of the total. Management said spending was below its intended pace because trial starts and patient recruitment influence expenditure, but expected a significant ramp-up in subsequent quarters and retained its FY27 guidance.
Conclusion
Sun Pharma has acknowledged that Ilumya's US slowdown was partly an execution issue rather than only a change in market conditions. The disclosure came as Global Innovative Medicines still grew 6.9% to USD356 million and as Ilumya continued to show reported momentum in markets including Japan, Romania and Brazil.
The next milestones are the November soft launch and subsequent full US launch for psoriatic arthritis, increased calls on rheumatologists and management's stated expectation of recovery over the next few quarters. Investors can also watch whether R&D spending rises from Rs 778.4 crore in Q2 FY27 as management plans while the company works toward closing the Organon transaction in Q4 FY27.


